A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica

被引:906
作者
Lucchinetti, CF
Mandler, RN
McGavern, D
Bruck, W
Gleich, G
Ransohoff, RM
Trebst, C
Weinshenker, B
Wingerchuk, D
Parisi, JE
Lassmann, H
机构
[1] Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA
[3] Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA
[4] George Washington Univ, Dept Neurol, Washington, DC USA
[5] Cleveland Clin Fdn, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44195 USA
[6] Lerner Res Inst, Dept Neurosci, Cleveland, OH USA
[7] Mayo Clin Scottsdale, Dept Neurol, Scottsdale, AZ USA
[8] Inst Brain Res, Vienna, Austria
[9] Charite, Dept Neuropathol, Berlin, Germany
关键词
Devic's syndrome; eosinophils; humoral immunity; neuromyelitis optica; neuropathology;
D O I
10.1093/brain/awf151
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Devic's disease [neuromyelitis optica (NMO)] is an idiopathic inflammatory demyelinating disease of the CNS, characterized by attacks of optic neuritis and myelitis. The mechanisms that result in selective localization of inflammatory demyelinating lesions to the optic nerves and spinal cord are unknown. Serological and clinical evidence of B cell autoimmunity has been observed in a high proportion of patients with NMO. The purpose of this study was to investigate the importance of humoral mechanisms, including complement activation, in producing the necrotizing demyelination seen in the spinal cord and optic nerves. Eighty-two lesions were examined from nine autopsy cases of clinically confirmed Devic's disease. Demyelinating activity in the lesions was immunocytochemically classified as early active (21 lesions), late active (18 lesions), inactive (35 lesions) or remyelinating (eight lesions) by examining the antigenic profile of myelin degradation products within macrophages. The pathology of the lesions was analysed using a broad spectrum of immunological and neurobiological markers, and lesions were defined on the basis of myelin protein loss, the geography and extension of plaques, the patterns of oligodendrocyte destruction and the immunopathological evidence of complement activation. The pathology was identical in all nine patients. Extensive demyelination was present across multiple spinal cord levels, associated with cavitation, necrosis and acute axonal pathology (spheroids), in both grey and white matter. There was a pronounced loss of oligodendrocytes within the lesions. The inflammatory infiltrates in active lesions were characterized by extensive macrophage infiltration associated with large numbers of perivascular granulocytes and eosinophils and rare CD3(+) and CD8(+) T cells. There was a pronounced perivascular deposition of immunoglobulins (mainly IgM) and complement C9neo antigen in active lesions associated with prominent vascular fibrosis and hyalinization in both active and inactive lesions. The extent of complement activation, eosinophilic infiltration and vascular fibrosis observed in the Devic NMO cases is more prominent compared with that in prototypic multiple sclerosis, and supports a role for humoral immunity in the pathogenesis of NMO. Based on this study, future therapeutic strategies designed to limit the deleterious effects of complement activation, eosinophil degranulation and neutrophil/macrophage/microglial activation are worthy of further investigation.
引用
收藏
页码:1450 / 1461
页数:12
相关论文
共 57 条
[41]  
Prineas J., 1997, GREENFIELDS NEUROPAT, P813
[42]  
RAO AS, 1981, INDIAN J CHEM B, V20, P159
[43]   Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice [J].
Rothenberg, ME ;
Ownbey, R ;
Mehlhop, PD ;
Loiselle, PM ;
vandeRijn, M ;
Bonventre, JV ;
Oettgen, HC ;
Leder, P ;
Luster, AD .
MOLECULAR MEDICINE, 1996, 2 (03) :334-348
[44]  
Rumbley CA, 1999, J IMMUNOL, V162, P1003
[45]   Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes [J].
Sallusto, F ;
Lenig, D ;
Mackay, CR ;
Lanzavecchia, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (06) :875-883
[46]   RACIAL MODIFICATION OF CLINICAL PICTURE OF MULTIPLE-SCLEROSIS - COMPARISON BETWEEN BRITISH AND JAPANESE PATIENTS [J].
SHIBASAKI, H ;
MCDONALD, WI ;
KUROIWA, Y .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1981, 49 (02) :253-271
[47]  
SIMEONAZNAR CP, 1992, BRIT J RHEUMATOL, V31, P555
[48]  
SNEAD OC, 1976, J PEDIATR-US, V89, P83
[49]   Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients [J].
Sorensen, TL ;
Tani, M ;
Jensen, J ;
Pierce, V ;
Lucchinetti, C ;
Folcik, VA ;
Qin, SX ;
Rottman, J ;
Sellebjerg, F ;
Strieter, RM ;
Frederiksen, JL ;
Ransohoff, RM .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (06) :807-815
[50]   Multiple sclerosis: In situ evidence for antibody and complement-mediated demyelination [J].
Storch, MK ;
Piddlesden, S ;
Haltia, M ;
Iivanainen, M ;
Morgan, P ;
Lassmann, H .
ANNALS OF NEUROLOGY, 1998, 43 (04) :465-471